Thyroid peroxidase (TPO) is a critical membrane-bound enzyme involved in the biosynthesis of 26 multiple thyroid hormones, and is a major autoantigen in autoimmune thyroid diseases such as 27 Graves' disease and Hashimoto's thyroiditis. Here we report the biophysical and structural 28 characterisation of two novel TPO constructs containing only the ectodomain of TPO and lacking the 29 propeptide. Both constructs were enzymatically active and able to bind the patient-derived TR1.9 30 autoantibody. Analytical ultra-centrifugation data suggests that TPO can exist as both a monomer 31 and a dimer. Combined with negative stain electron microscopy and molecular dynamics 32 simulations, these data show that TR1.9 autoantibody preferentially binds the TPO monomer, 33 revealing conformational changes that bring together previously disparate residues into a 34 continuous epitope. In addition to providing plausible structural models of a TPO-autoantibody 35 complex, this study provides validated TPO constructs that will facilitate further characterization, 36 and advances our understanding of the structural, functional and antigenic characteristics of TPO, a 37 molecule behind some of the most common autoimmune diseases. 38 39 40 41 48 (Hashimoto's disease) and hyperthyroidism (Grave's disease) 2,3. AITDs are some of the most 49 common autoimmune diseases in the developed world, with Hashimoto's disease being a strong risk 50 factor for thyroid cancer 4. TPO is suspected to be involved in the pathogenesis of Hashimoto's 51 thyroiditis (prevalence 300-2980 cases per 100,000 in the Western world), leading to thyrocyte 52 destruction via CD8+ T-cell infiltration resulting in hypothyroidism 1,3,5. This incidence rate can be 53 compared to other autoimmune diseases -for example type 1 diabetes, which has an incidence in 54 the developed world of 310-570 cases per 100,000 patients -demonstrating the immense disease 55 burden caused by AITDs 5. The pathogeneses that underlies these autoimmune diseases is complex, 56 however the lack of any tertiary or quaternary structure of TPO complicates matters. The absence of 57 a structure in which to understand binding of anti-TPO antibodies, which are prevalent almost 58 ubiquitously (>95%) in cases of destructive thyroiditis, complicates the understanding of the 59 pathogenesis and nature of the disease. The precise mechanism by which these antibodies cause 60 damage is uncertain 2. Additionally, in some cases AITDs can occur without these autoantibodies 61 being present, and transplacental passage of anti-TPO antibodies does not necessarily cause thyroid 62 damage in the offspring 3,6,7. Despite this, transplacental passage of these autoantibodies can 63 potentially have cognitive effects on the child. In addition, antibodies to thyroglobulin (Tg) and 64 thyroid stimulating hormone receptor have been identified in both conditions, indicating that there 65 may be multiple antigens in AITD pathogenesis 2.
Introduction

43
Thyroid Peroxidase (TPO) is an enzyme in the thyroid gland responsible for oxidising iodide ions 44 to form iodine (mediated by hydrogen peroxide), which can then be incorporated into the key 45 thyroid hormones triiodothyronine (T3) and thyroxine (T4) 1. These hormones are critical in the 46 regulation of metabolism. TPO is of clinical significance, as it is a target of autoantibodies and 47 autoreactive T cells in autoimmune thyroid diseases (AITD) such as destructive thyroiditis 7 culture, in addition to polyethylenimine at a rate of 4µg per 1µg of DNA. Cells were counted and 140 adjusted to 1.5x106 cells/mL which had >95% viability for transfection. This buffer was added to the 141 culture to an amount equal to 10% of the final volume. Glucose concentration was adjusted to 33 142 mmol/L, and the cells were incubated at 37°C with 5% CO2 for 7 days. Final concentrations of 20 µM 143 hematin and 10 µM hydrogen peroxide were added to the culture twice during the course of ΔproTPOe-8His and ΔproTPOe-GCN4 was incubated in two-fold molar excess of TR1.9 Fab, in 1x 181 PBS, pH 7.4 supplemented with + 0.01% Tween 20. This complex was incubated at 4 °C for 30 182 minutes before injection onto a Superdex S200 16/60 size-exclusion column (GE Healthcare). The 183 sample was run at 1.0 mL/min and eluted in 1.5 mL fractions, before being analysed by SDS-PAGE.
185
Western blot analysis 186 Following SDS-PAGE analysis, the proteins on the gel were transferred to a PVDF membrane at 187 100V for one hour. The membrane was then blocked in 5% skim milk in PBST-0.05 at room 188 temperature for one hour with shaking. Constructs containing a His tag were detected by a single Facility. Peptide fragments were compared against a reference ΔproTPOe-GCN4 sequence.
201
Guaiacol activity assay 202 TPO can also oxidise the compound guaiacol, which remains colourless in solution, to 203 tetraguaiacol, which appears orange. This characteristic can be exploited by spectroscopic analysis 204 to record the enzymatic activity of TPO. This reaction was undertaken in 96-well plates, with each 205 reaction containing 0.1 mg/mL TPO sample, 1 mM hydrogen peroxide, 33 mM guaiacol and TPO.
206
Detection via a Bio-Rad 96-well plate reader occurred after a 5-minute incubation for these 207 reagents, at 450 nm. We also recorded this interaction over time, comparing with a HRP-conjugated 208 antibody (ThermoFisher Scientific, 1 in 1000 dilution) and a PBS blank for controls, recording optical 209 density over time.
211
Soret peak analysis to determine incorporation of heme group 212
The successful incorporation of an iron containing heme group in proteins can be detected by 213 what is known as a Soret peak. ΔproTPOe-8His and ΔproTPOe-GCN4 at a concentration of 0.5 214 mg/mL in 1x PBS pH 7.4 were placed in a cuvette and a fluorescence spectrum was obtained, with an 215 incident wavelength of 330 nm. A distinctive peak at 385 nm is a Soret peak and is distinctive of 216 hemoproteins. This absorbance spectrum was obtained on a HoribaJobinYvon FluoroMax4 10 spectrophotometer.
219
Protein stability measurements 220 TPO constructs at a final concentration of 0.3 mg/mL were placed in different buffer conditions 221 ranging from pH 4.0 to 8.0 (Table S2) 
272
These residues were weakly constrained with harmonic position restrains of 2 kcal Å2 mol−1. These 273 proteins contained protonation states appropriate for pH 7.0 (as determined by PROPKA) and were 274 inserted in a rectangular box with a border with a minimum of 12 Å 21,22. They were then explicitly 275 solvated with TIP3P water, sodium counter-ions were added and then the system was 276 parameterised using the AMBER ff99SB forcefield 23-26. After 10000 steps of energy minimisation, an 277 equilibration stage was performed. The temperature was raised from 0 K to 300 K with a constant 278 volume and a 10 K ramp over 1 ns, with Langevin temperature coupling relaxation times of 0.5 ps.
279
After the target temperature was achieved, the pressure was equilibrated to 1 atm using the
280
Berendsen algorithm over 0.5 ps 27. The MD simulations used periodic boundary conditions and a 281 time step of 2 fs, with temperature maintained at 300 K using the Langevin thermostat and pressure 282 maintained at 1 atm using the Berendsen method as described above. All MD simulations were run 283 in triplicate, with the same starting structure but with altered starting velocities following the 284 equilibration and parametrisation steps. Each run extended for 400 ns using NAMD 2.9 28. 
289
with the RMSD of backbone heavy atoms in relation to the initial structure calculated for every 0.1 290 ns of simulation after calculating a least-square fit. Output structures for further analysis were 291 selected from a plateau in the RMSD calculation, whereby the structure adopted a stable state.
292
Distance between selected IDR residues in each frame was also calculated using VMD and custom 
302
The ΔproTPOe-8His construct lacks a propeptide domain, which has previously been shown to not 303 influence TPO secretion, activity or immunogenicity 17. Additionally, the expression of only the 304 ectodomain allows ΔproTPOe-8His to be secreted into the media rather than be retained in the 305 membrane. ΔproTPOe-8His was expressed into the media successfully in EXPI293 cells ( Figure 2 ).
306
Purification of the secreted media shows the presence of a major band ~110 kDa that is ∆proTPOe-307 8His. Upon a two-step purification involving Ni-NTA affinity chromatography and size-exclusion on a 308 Superdex S200 16/60 column, ΔproTPOe-8His elutes as a single symmetrical peak at 75.5 mL which 309 is consistent with that of a 110 kDa according to our calibration ( Figure 2C ). There appears to be no 310 other high molecular weight species on the chromatogram. Despite this, the fractions making up this 311 peak when analysed via reducing SDS-PAGE ( Figure 2A ) demonstrate a number of minor species,
312
which may be due the heterogeneous nature of the glycosylation of TPO or protein degradation 313 from proteases released from cells during the 7-day expression cycle.
314
In an attempt to favour TPO dimerisation we engineered a GCN4 leucine zipper dimerisation 315 motif into the C-terminus of TPO, creating ΔproTPOe-GCN4. Expression and purification proceeded 316 as with the ΔproTPOe-8His construct ( Figure S1 ). SDS-PAGE followed by mass spectroscopic analysis 317 confirmed the presence of intact ΔproTPOe-GCN4 (~110 kDa) ( Figure S2 ). Despite the quality of our 318 preparations, TPO suffered from a shorter shelf life and often appeared to degrade into a 75kDa 319 component according to SDS-PAGE. This fragment was analysed by mass spectrometry and was 320 identified as a truncated TPO ( Figure S3 ). Enzymatic activity of the constructs was validated by 321 spectroscopic analysis, measuring both proper heme incorporation as well as function via the 322 guaiacol activity assay ( Figure 3 ). Whereas ΔproTPOe-8His is enzymatically active, activity could not 323 be detected for ΔproTPOe-GCN4 (data not shown).
15
ΔproTPOe-8His shows statistically significant activity, suggesting that this protein is likely 325 enzymatically active and correctly folded ( Figure 3B ). Since the thermal stability of TPO has not been 326 reported to date, we measured the stability of the ΔproTPOe-8His construct using thermal unfolding 327 and monitoring intrinsic tryptophan fluorescence in several buffer conditions. The midpoint of 328 unfolding (Tm) of ΔproTPOe-8His reached a maximum of 55.2 C at pH 7.0 (Table S2 ). We next 329 showed that TR1.9 Fab binding completely inhibits the catalytic activity of TPO ( Figure 3C ). Table S3 .
353
Characterisation of a human TPO-autoantibody complex
354
In order to gain insight into the nature of the interaction between TPO and the patient-derived 355 TR1.9 autoantibody, we expressed the Fab portion of TR1.9 as previously described 18. TR1.9 Fab was 356 shown to bind both ΔproTPOe-8His and ΔproTPOe-GCN4 using ELISA ( Figure 5 ). It is apparent from 357 the size-exclusion chromatogram that Fab binds to full-length ΔproTPOe-8His ( Figure 5A ). There was 358 only a minor peak shift with no appearance of any large species on the chromatogram (dimeric TPO 359 with two Fabs would exceed 320 kDa), which would suggest a stoichiometric monomeric TPO-Fab 360 complex. We also calculated the Stokes radii of the various TPO constructs with and without Fab 361 using analytical size-exclusion chromatography as well as AUC (Table S3 ). Bio-layer interferometry 362 indicated that ΔproTPOe-8His binds TR1.9 Fab with an affinity of 20 nM ( Figure S4 ). Taken together, 363 this data confirms the antigenic quality of our constructs.
365
Analytical Ultra-centrifugation of the ΔproTPOe-GCN4-TR1.9 Fab Complex
366
We next used analytical ultra-centrifugation to investigate the association between TR1.9 Fab
367
and ΔproTPOe-GCN4, as well as the effect of TR1.9 Fab binding on the equilibrium of monomer and 368 dimer TPO species. The sedimentation coefficient for TR1.9 Fab alone was determined as sw(20,w) = 369 2.6S. AUC analysis of an equimolar mixture of TR1.9 Fab and ΔproTPOe-GCN4 shows two peaks 370 ( Figure 5C ). The lack of a peak at 2.6S suggests that none, or very little of the Fab, remained un-371 complexed. Therefore, the two remaining peaks are most likely the TPO monomer/dimer peaks as 372 observed in the previous experiment ( Figure 4A ). The observed shift in their standardised weight-373 average sedimentation coefficients (4.1S, 6.6S, respectively) suggest a change in their shape and 374 mass, indicating Fab binding to both monomer and dimer ΔproTPOe-GCN4. The frictional ratio has 375 also changed to 1.77 (from 2.36 with ΔproTPOe-GCN4 alone), indicating that TPO has taken a more spherical shape upon TR1.9 Fab binding. Importantly, the ratio of monomer and dimer has shifted to 377 approximately 2:1. This indicates that TR1.9 Fab preferentially binds the TPO monomer, thus 378 perturbing the monomer:dimer equilibrium.
380
Analytical Ultracentrifugation of ΔproTPOe-8His with TR1.9 Fab
381
The same sedimentation velocity experiments were undertaken with ΔproTPOe-8His in the 382 presence of TR1.9 Fab, with the Fab in 2-fold excess of TPO. Two distinct species were observed 383 ( Figure 5D ), with a standardised weight-average sedimentation coefficient of 2.8 and 3.9. This is 384 largely consistent with the Fab alone (2.6S) and ΔproTPOe-GCN4 monomer plus TR1.9 Fab (4.1S)
385
data obtained previously with the alternate construct. Interestingly, in this case there appears to be 386 no other large species, indicating that the binding of Fab has pushed the monomer:dimer 387 equilibrium such that all ΔproTPOe-8His exists exclusively in its monomeric form. AUC further shows 388 that TR1.9 Fab can successfully bind both TPO constructs.
389
The monomeric ΔproTPOe-8His with Fab has a frictional ratio of 1.90 and a Stokes radius of 57.4, 390 similar to that of the monomeric form of ΔproTPOe-GCN4 bound with Fab (Table S3) 
414
As a result, the average residue separation within the epitope decreases from 56 to 40 Å, reaching 415 21 Å at some points in the simulation. This distance is such that it could reasonably be engaged by a 416 single autoantibody via a continuous epitope, which may suggest a mechanism by which 417 autoantibodies could engage multiple sites on TPO that in previous modelling may appear distant.
418
The trans model of TPO behaved in a similar manner during simulation, decreasing its maximum 419 dimension from 100 to 82 Å. In contrast however, the CCP-like and EGF-like domains (again 420 containing the same epitope) tended to coalesce around the reported T13 epitope residues K713-421 S720 on the MPO-like domain, which is also close to R225 and D707 epitope residues (Figures 7, 8 our MD simulation suggest that all residues involved in these four epitopes are no more than 43 Å 431 away from all other residues in the set of 39 residues previously implicated in the T13 epitope
432
( Figures 8C & S6B) . Taken together, these observations may suggest a mechanism not only by which
433
TPO can alter its conformation to take a more compact and globular structure, but potentially 434 explain how disparate residues involved in the IDRs may compact to form a discrete, continuous 435 epitope.
437
Analysis of TPO Structure Using Negative Stain Electron Microscopy
438
We next investigated the structure of the ∆proTPOe-8His construct in complex with TR1.9 Fab (Table S4 ).
469
Given the orthogonal agreement within the presented data from SEC, BLItz, ELISA and AUC 470 analysis indicating we have a high affinity binding interaction between ∆proTPOe-8His and TR1.9
471
Fab, it is unlikely that the Fab is not contained with the EM envelope. Unbound monomer or dimers 472 are thus unlikely. Given that AUC analysis suggests that TR1.9 Fab binds to a TPO monomer and 473 adopts a compact shape upon complexation that is consistent with our MD analysis ( Figures 5 and   474 6), the EM data suggests strongly that at least in its non-membrane bound form, TR1.9 binds to TPO 475 as a monomer. 
496
Both ΔproTPOe-8His and ΔproTPOe-GCN4 constructs showed an approximately 75kDa 497 degradation product after the initial purification, which co-eluted with the full-length protein during 498 size-exclusion chromatography. This behavior may be due to instability or altered glycosylation, 499 which could account for upto 25% of TPO's 110 kDa molecular mass. There are many splice variants 500 of TPO that have been characterised, indicating its complicated biosynthesis and the relevance of 501 our engineered constructs in providing a consistent protein product 40,44. It is now known that there 502 is more than 10 TPO isoforms 10. Given the importance of glycosylation in the folding and post-503 22 translational trafficking of TPO 9 45, it is unlikely that non-post-translationally modified TPO would be 504 exported. A mere 2% of TPO synthesised by cells reaches the cell surface as most is degraded by 505 proteases or the proteasome due to partial or complete misfolding 45. It is possible that during the 7-506 day time course for expression, proteolytic activity, rather than inherent instability may have led to 507 the observed degradation, consistent with our thermal stability data.
508
There exists evidence for both monomeric and dimeric forms of TPO, and no consensus 509 agreement on its physiological oligomerization state 17,46-48. Bioinformatic analysis of the peroxidase 510 family is consistent with both monomer and dimer. LPO is the most closely related protein to TPO, 511 with 48% sequence identity between their MPO-like domains, and is functionally monomeric 1. MPO,
512
with 47% sequence identity with TPO, is an active dimer stabilized by intermolecular disulfide bonds 513 via a conserved Cys296, which is also conserved in TPO 48. As such, the MPO-like domain of TPO has 514 been modelled exclusively upon the MPO homodimer. Given however that much of the epitope 515 mapping data suggests that autoantibodies disproportionately recognise epitopes of the MPO-like 516 domain of TPO, and that to date TPO dimerization has not been investigated in any detail, a greater 517 understanding of its oligomerization state would be a great benefit in understanding its 518 autoantigenicity 49. Some insights may be gleaned from studies on MPO, given its common ancestry 519 and function with TPO. MPO dimerisation occurs in the secretory pathway during proteolytic 520 processing 16. In TPO biosynthesis, the propeptide is cleaved after exit from the Golgi apparatus and 521 dimerisation is likely to occur prior to reaching the plasma membrane 10. As such, dimerisation may 
528
AUC analysis of the ΔproTPOe-GCN4 construct is consistent with a monomer:dimer equilibrium, slightly favoring the monomer. TR1.9 Fab binds the monomer preferentially, shifting the equilibrium 530 to 2:1, suggesting a role of the autoantibody in the monomer-dimer interplay. However, since the 531 GCN4 leucine zipper was introduced as a dimerisation motif, any affect on dimerization by Fab-532 binding must be interpreted with caution. AUC analysis for ΔproTPOe-8His construct follows similar 533 behavior in that it can exist as both monomer and dimer, with only the monomer binding to TR1.9
534
Fab. Interestingly, whereas the ΔproTPOe-8His construct was enzymatically active, the ΔproTPOe-
535
GCN4 construct was not, suggesting that either the dimer interface may occlude the active site of 536 the protein, or that GCN4 interferes with activity via another mechanism. Inspection of epitope 537 mapping data on the cis model of dimeric TPO indicates that several residues that comprise 538 immunodominant regions are buried. Furthermore, the large and diffuse nature of IDR-A and -B 539 determinants in both cis and trans models suggest that significant conformational changes would be 540 necessary to form a continuous epitope compatible with antibody engagement 8. Some residues 541 may be surface exposed, but the dimer conformation may prevent autoantibody binding due to 542 steric occlusion. In support of this, AUC analysis shows that the TPO-Fab complex undergoes a large 543 conformational change to become more compact, and also that TR1.9 Fab preferentially binds the 544 monomer, thus shifting the monomer:dimer equilibrium.
545
Our EM analysis provides the first ever structural glimpse regarding information about the 546 ectodomain of TPO. Although the EM resolution is limited, it is consistent with our other data,
547
allowing us with high confidence to eliminate a complex between Fab and a TPO dimer.
548
Furthermore, the EM data strongly supports our SEC and AUC analysis showing that ΔproTPOe-8His 549 is a monomer when bound to TR1.9 Fab. Modelling of TPO has suggested that membrane bound 550 TPO is an elongated molecule with domains outstretched, however our experimental EM and AUC 551 data suggests that at least for the TPO ectodomain, a much more globular and compact space is 552 taken up in solution, especially when bound to its cognate antibody. This experimental data is 553 supported by MD simulations of ΔproTPOe in its non-membrane bound form, whereby TPO is able 554 to undergo large changes in conformation ( Figure S6 ). Thus, MD simulations, AUC and EM provide 555 24 convincing evidence that TPO is able to coalesce into a more compact, globular structure in solution.
556
Furthermore, MD analysis reveals how the TPO monomer can change shape such that residues 557 implicated in autoantibody binding that are disparate in space can be bought together to form a 558 continuous epitope. However, we cannot from this data suggest definitively that this is the 559 conformation of TPO when bound to T13 autoantibody. Instead, we argue that our data suggest that 560 TPO may be able to change conformation in such a fashion that previously distal epitopes can 561 coalesce into one discrete, continuous epitope. This may explain the previously conflicting epitope 562 mapping data for some autoantibodies in IDR-A and IDR-B that contained residues that were too far 563 from each other to be engaged by the CDRs of a single autoantibody, based on previous modelling.
564
Despite previous attempts to resolve this issue 14,15, a definitive answer, however, awaits a high-
565
resolution structure for TPO alone and in complex with cognate autoantibodies.
566
All of our analysis, including MD, considers TPO in solution. We expect that the conformational, 
